Navigation Links
Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Date:8/18/2008

Company's Complete Portfolio of Transfusion Solutions Offers Choice,

Opportunity for Blood Bank Industry

ROCKAWAY, N.J., Aug. 18 /PRNewswire/ -- Biotest Diagnostics Corporation (Biotest) -- the U.S. subsidiary of German-based Biotest AG, a worldwide supplier of traditional and automated blood bank solutions -- announces that it has received final clearance from the U.S. Food and Drug Administration (FDA) to begin marketing its full line of traditional blood bank reagents in North America. Intended for use by donor centers, reference laboratories and hospitals for blood group serology testing, these traditional blood bank reagents complement Biotest's existing portfolio of automated reagents that work with its TANGO|optimo Automated Blood Bank System. The availability of these additional reagents afford customers more comprehensive, cost-effective choices -- marking a major milestone for Biotest and the transfusion medicine industry.

"The ability to efficiently and accurately screen and type blood, as well as match patients and donors is critical, as are the tools we provide the blood banking industry," said Bill Weiss, president, Biotest. "The approval of our traditional reagent line provides laboratory professionals with a vital alternative for their testing needs. Accessibility to more options at competitive prices is a significant offering in today's competitive market. And, as a full-service supplier for laboratories' complete blood typing and testing needs, Biotest is not only helping to strengthen the industry, but is also solidifying its unyielding commitment to customers and their patients."

The traditional reagents that received FDA clearance include:

-- Seraclone(R) Blood Grouping Reagents

-- Biotestcell(R) Reagent Red Blood Cells

-- Rare Typing Reagents

-- Anti-Human Globulins

-- Enhancement Reagents

-- Control Sera and Red Cells

Biotest's Reagent Red Blood Cell products include three configurations for antibody screening, two antibody identification panels, Coombs control cells and reverse ABO products. Rare typing reagents will include anti-C, anti-E, anti-c, anti-e, anti-Lea, anti-K, anti-k, anti-Fya, anti-Jka, anti-Jkb, anti-M, anti-N, anti-S, anti-s and anti-P1. All antisera are monoclonal and many of the clones have never been previously available in the U.S. Biotest's reagents are recognized for their high levels of sensitivity and specificity and are competitively priced.

Supporting its reagents and the TANGO|optimo, which features a newly expanded test menu that recently received FDA clearance, Biotest provides a 24/7 tech support hotline to ensure that its customers receive fast and knowledgeable answers to their questions. Biotest's specially trained blood bank field staff -- comprised of medical technologists with donor center and hospital transfusion service experience, and field service engineers with years of diagnostic industry experience -- are on call and available to support implementation that is customized to meet the individual facility's needs and provide fast and effective on-site troubleshooting.

About Biotest

Biotest AG along with its U.S. subsidiary, Biotest Diagnostics Corporation located in Rockaway, N.J., are expecting to strengthen their leadership position in the transfusion diagnostic market with the U.S. introduction of a complete line of traditional and automated serology products for use in blood banks and transfusion services. Biotest AG is a global healthcare company focused on test systems for transfusion and transplant diagnostics as well as clinical immunoglobulin preparations, blood coagulation factors, and environment monitoring. Biotest AG introduced the first test serum for Anti-D -- used to determine the Rh factor -- in 1948 and today is represented in 130 countries with products sold worldwide. For more information about Biotest's blood typing and testing solutions, call 800-522-0090, e-mail info@biotestusa.com or visit Biotest at http://www.biotestusa.com.


'/>"/>
SOURCE Biotest Diagnostics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biotest Pharmaceuticals Corporation Announces Management Team
2. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
3. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
4. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
5. DeviceSpace(TM) to Host Medical Device and Diagnostics Career Fair in Minneapolis
6. Quest Diagnostics to Release Second Quarter 2008 Financial Results
7. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
8. Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance
9. HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
10. ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon
11. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):